Long-Term Assets: The sum of all assets classified as non-current.
Atrium Therapeutics, Inc. (RNA) had Long-Term Assets of 35.11M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
0.86M |
|
-237.10M |
|
-- |
|
0.86M |
|
88.74M |
|
-87.88M |
|
17.38M |
|
-237.10M |
|
-237.10M |
|
-237.10M |
|
-237.10M |
|
-237.10M |
|
-237.10M |
|
-87.88M |
|
-87.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
1.80B |
|
35.11M |
|
|
Long-Term Assets |
35.11M |
1.96B |
|
195.45M |
|
-- |
|
-- |
|
269.45M |
|
-1.58B |
|
1.69B |
|
1.69B |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-10218.84% |
|
-10218.84% |
|
-- |
|
-27569.88% |
|
-27569.88% |
|
-- |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
15.03% |
|
-14.04% |
|
-12.11% |
|
-14.04% |
|
-- |
|
-- |
|
-- |
|